Quentin A Hill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2695061/publications.pdf

Version: 2024-02-01

43 papers 1,678 citations

393982 19 h-index 39 g-index

52 all docs 52 docs citations

52 times ranked 1790 citing authors

#	Article	IF	CITATIONS
1	A realâ€world study of immune thrombocytopenia management during the COVIDâ€19 pandemic in the UK. British Journal of Haematology, 2022, 196, 351-355.	1.2	12
2	Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies. European Journal of Cancer, 2022, 162, 158-160.	1.3	3
3	Functional impairment of erythropoiesis in Congenital Dyserythropoietic Anaemia type I arises at the progenitor level. British Journal of Haematology, 2022, , .	1.2	O
4	Incidence of adult primary immune thrombocytopenia in England—An update. European Journal of Haematology, 2022, 109, 238-249.	1.1	5
5	Genetic and functional insights into CDA-I prevalence and pathogenesis. Journal of Medical Genetics, 2021, 58, 185-195.	1.5	9
6	Real-world experience with caplacizumab in the management of acute TTP. Blood, 2021, 137, 1731-1740.	0.6	93
7	Developing the evidence base for the management of autoimmune haemolytic anaemia (AIHA): the UK experience. British Journal of Haematology, 2021, 192, e54-e57.	1.2	5
8	Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel. Acta Haematologica, 2021, 144, 418-426.	0.7	17
9	Organ transplantation from deceased donors with vaccine-induced thrombosis and thrombocytopenia. American Journal of Transplantation, 2021, 21, 4095-4097.	2.6	13
10	Mycophenolate Mofetil for First-Line Treatment of Immune Thrombocytopenia. New England Journal of Medicine, 2021, 385, 885-895.	13.9	53
11	Recapitulation of erythropoiesis in congenital dyserythropoietic anemia type I (CDA-I) identifies defects in differentiation and nucleolar abnormalities. Haematologica, 2021, 106, 2960-2970.	1.7	10
12	Psychometric Evaluation of ITP Life Quality Index (ILQI) in a Global Survey of Patients with Immune Thrombocytopenia. Advances in Therapy, 2021, 38, 5791-5808.	1.3	5
13	Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood Reviews, 2020, 41, 100648.	2.8	267
14	Fostamatinib is an effective secondâ€line therapy in patients with immune thrombocytopenia. British Journal of Haematology, 2020, 190, 933-938.	1.2	38
15	Practical guidance for the management of adults with immune thrombocytopenia during the COVIDâ€19 pandemic. British Journal of Haematology, 2020, 189, 1038-1043.	1.2	89
16	Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Advances, 2019, 3, 1897-1906.	2.5	69
17	Novel insights into the treatment of complement-mediated hemolytic anemias. Therapeutic Advances in Hematology, 2019, 10, 204062071987332.	1.1	65
18	Changes in critically ill cancer patients' short-term outcome over the last decades: results of systematic review with meta-analysis on individual data. Intensive Care Medicine, 2019, 45, 977-987.	3.9	100

#	Article	IF	CITATIONS
19	The prevention of glucocorticoidâ€induced osteoporosis in patients with immune thrombocytopenia receiving steroids: aÂBritish Society for Haematology Good Practice Paper. British Journal of Haematology, 2019, 185, 410-417.	1.2	10
20	The Psychometric Properties of the ITP Life Quality Index Assessed in a Large Multinational "Real-World" Cohort of Immune Thrombocytopaenia Patients. Blood, 2019, 134, 386-386.	0.6	3
21	A United Kingdom Immune Thrombocytopenia (<scp>ITP</scp>) Forum review of practice: thrombopoietin receptor agonists. British Journal of Haematology, 2018, 180, 591-594.	1.2	7
22	Immune thrombocytopenia – in defence of the platelet count. British Journal of Haematology, 2018, 182, 128-130.	1.2	3
23	Immune thrombocytopenia: improving quality of life and patient outcomes. Patient Related Outcome Measures, 2018, Volume 9, 369-384.	0.7	44
24	Influence of neutropenia on mortality of critically ill cancer patients: results of a meta-analysis on individual data. Critical Care, 2018, 22, 326.	2.5	37
25	Trial protocol: a multicentre randomised trial of first-line treatment pathways for newly diagnosed immune thrombocytopenia: standard steroid treatment versus combined steroid and mycophenolate. The FLIGHT trial. BMJ Open, 2018, 8, e024427.	0.8	20
26	Autoimmune hemolytic anemia. Hematology American Society of Hematology Education Program, 2018, 2018, 382-389.	0.9	93
27	Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program. Blood, 2018, 132, 736-736.	0.6	6
28	Real World Use of Thrombopoietin-Receptor Agonists in the Management of Immune Thrombocytopenia in the United Kingdom: Results from the TRAIT Study. Blood, 2018, 132, 2426-2426.	0.6	1
29	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. Tumor Biology, 2017, 39, 101042831769979.	0.8	45
30	Guidelines on the management of drugâ€induced immune and secondary autoimmune, haemolytic anaemia. British Journal of Haematology, 2017, 177, 208-220.	1.2	93
31	The diagnosis and management of primary autoimmune haemolytic anaemia. British Journal of Haematology, 2017, 176, 395-411.	1.2	164
32	Donors With Immune Thrombocytopenia: Do They Pose a Risk to Transplant Recipients?. American Journal of Transplantation, 2017, 17, 796-802.	2.6	11
33	A fatal case of transplantation-mediated alloimmune thrombocytopenia following liver transplantation. Hematology, 2017, 22, 162-167.	0.7	13
34	Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. Blood Advances, 2017, 1, 1159-1166.	2.5	84
35	Autoimmune haemolytic anaemia. ISBT Science Series, 2016, 11, 85-92.	1.1	4
36	How does dapsone work in immune thrombocytopenia? Implications for dosing. Blood, 2015, 125, 3666-3668.	0.6	11

QUENTIN A HILL

#	Article	IF	CITATIONS
37	Autoimmune hemolytic anemia. Hematology, 2015, 20, 553-554.	0.7	5
38	Disappointing response to dapsone as second line therapy for primary ITP: a case series. Annals of Hematology, 2015, 94, 1053-1054.	0.8	7
39	A combination of two novel alpha globin variants Hb Bridlington (<i>HBA1</i>) and Hb Taybe (<i>HBA2</i>) resulting in severe hemolysis, pulmonary hypertension, and death. Hematology, 2015, 20, 50-52.	0.7	8
40	Fatigue in immune thrombocytopenia. British Journal of Haematology, 2015, 170, 141-149.	1.2	62
41	Survival of patients with hematological malignancy admitted to the intensive care unit: prognostic factors and outcome compared to unselected medical intensive care unit admissions, a parallel group study. Leukemia and Lymphoma, 2012, 53, 282-288.	0.6	30
42	Intensify, resuscitate or palliate: Decision making in the critically ill patient with haematological malignancy. Blood Reviews, 2010, 24, 17-25.	2.8	53
43	Towards better blood transfusion - recruitment and training. Transfusion Medicine, 2009, 19, 2-5.	0.5	6